224 related articles for article (PubMed ID: 28741484)
21. New Agents to Treat Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Seymour JF
N Engl J Med; 2016 Jun; 374(22):2186-7. PubMed ID: 27248631
[No Abstract] [Full Text] [Related]
22. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
Crombie J; Davids MS
Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
[TBL] [Abstract][Full Text] [Related]
23. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F; Larkin K; Gregory CT; Orwick S; Doong TJ; Lozanski A; Lozanski G; Misra S; Ngankeu A; Ozer HG; Sampath D; Thangavadivel S; Yilmaz SA; Rogers KA; Byrd JC; Woyach JA; Blachly JS
Blood; 2020 Jun; 135(24):2192-2195. PubMed ID: 32232486
[No Abstract] [Full Text] [Related]
24. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
[TBL] [Abstract][Full Text] [Related]
25. Venetoclax targets BCL2 in chronic lymphocytic leukaemia.
Brower V
Lancet Oncol; 2016 Jan; 17(1):e11. PubMed ID: 26687593
[No Abstract] [Full Text] [Related]
26. BCL2 and miR-15/16: from gene discovery to treatment.
Pekarsky Y; Balatti V; Croce CM
Cell Death Differ; 2018 Jan; 25(1):21-26. PubMed ID: 28984869
[TBL] [Abstract][Full Text] [Related]
27. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.
Birkinshaw RW; Gong JN; Luo CS; Lio D; White CA; Anderson MA; Blombery P; Lessene G; Majewski IJ; Thijssen R; Roberts AW; Huang DCS; Colman PM; Czabotar PE
Nat Commun; 2019 Jun; 10(1):2385. PubMed ID: 31160589
[TBL] [Abstract][Full Text] [Related]
28. ABT-199 shows effectiveness in CLL.
Cancer Discov; 2014 Sep; 4(9):OF7. PubMed ID: 25185206
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax resistance and acquired
Tausch E; Close W; Dolnik A; Bloehdorn J; Chyla B; Bullinger L; Döhner H; Mertens D; Stilgenbauer S
Haematologica; 2019 Sep; 104(9):e434-e437. PubMed ID: 31004028
[No Abstract] [Full Text] [Related]
30. Progress in Chronic Lymphocytic Leukemia with Targeted Therapy.
Wilson WH
N Engl J Med; 2016 Jan; 374(4):386-8. PubMed ID: 26816016
[No Abstract] [Full Text] [Related]
31. The rosy future of BCL-2 inhibition in chronic lymphocytic leukemia: pursuit of a worthy target.
Brown JR
Leuk Lymphoma; 2015; 56(10):2755-6. PubMed ID: 25971908
[No Abstract] [Full Text] [Related]
32. MicroRNA Dysregulation to Identify Novel Therapeutic Targets.
Croce CM
Curr Top Microbiol Immunol; 2017; 407():191-203. PubMed ID: 28653191
[TBL] [Abstract][Full Text] [Related]
33. The BCL-2 arbiters of apoptosis and their growing role as cancer targets.
Adams JM; Cory S
Cell Death Differ; 2018 Jan; 25(1):27-36. PubMed ID: 29099483
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
Huelsemann MF; Patz M; Beckmann L; Brinkmann K; Otto T; Fandrey J; Becker HJ; Theurich S; von Bergwelt-Baildon M; Pallasch CP; Zahedi RP; Kashkar H; Reinhardt HC; Hallek M; Wendtner CM; Frenzel LP
Leukemia; 2015 Apr; 29(4):981-4. PubMed ID: 25376373
[No Abstract] [Full Text] [Related]
36. The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Lampson BL; Davids MS
Curr Hematol Malig Rep; 2017 Feb; 12(1):11-19. PubMed ID: 28116634
[TBL] [Abstract][Full Text] [Related]
37. Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
Popovic R; Dunbar F; Lu C; Robinson K; Quarless D; Warder SE; Mukherjee N; Pesko J; Souers AJ; Waring JF; Davids MS; Tausch E; Stilgenbauer S; Ross JA; Leverson JD; Kim SY; Chyla BJ
Am J Hematol; 2022 Feb; 97(2):E47-E51. PubMed ID: 34779028
[No Abstract] [Full Text] [Related]
38. BCL2 blockade overcomes MCL1 resistance in multiple myeloma.
Siu KT; Huang C; Panaroni C; Mukaihara K; Fulzele K; Soucy R; Thorburn C; Cidado J; Drew L; Chattopadhyay S; Raje N
Leukemia; 2019 Aug; 33(8):2098-2102. PubMed ID: 30816329
[No Abstract] [Full Text] [Related]
39. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
Carter BZ; Tao W; Mak PY; Ostermann LB; Mak D; McGeehan G; Ordentlich P; Andreeff M
Blood; 2021 Oct; 138(17):1637-1641. PubMed ID: 34232981
[No Abstract] [Full Text] [Related]
40. Therapeutic inhibition of BCL-2 and related family members.
Levy MA; Claxton DF
Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]